Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD.
Long X, Wang H, Lu Y, Gao X, Xiao Y, Zhang M, Guo J, Yang J, Zhang R, Li Q, Zhou G, Yang R, Chen F, Wu Q, Sun L, Chu C, Zhu X, Wu Z, Ren Q, You C, Liu Z, Li Q, Liu D, Cheng D, Kang P, Chen A, Wu Q, Fang Q, Wei L, Zhang L, Li J, Panagiotou G, Jia W, Zeng R, Ni Y, Chen L, Li H.
Long X, et al.
Cell Metab. 2025 Dec 2;37(12):2342-2361.e9. doi: 10.1016/j.cmet.2025.10.017. Epub 2025 Nov 20.
Cell Metab. 2025.
PMID: 41270737
Free article.
Clinical Trial.
Our randomized, placebo-controlled trial showed resistant starch (RS), a type of prebiotic, has therapeutic effects in metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we observed its heterogeneous efficacy, where 30% of participants exhibited …
Our randomized, placebo-controlled trial showed resistant starch (RS), a type of prebiotic, has therapeutic effects in metabol …